首页> 美国卫生研究院文献>Critical Care >Why high suPAR is not super - diagnostic prognostic and potential pathogenic properties of a novel biomarker in the ICU
【2h】

Why high suPAR is not super - diagnostic prognostic and potential pathogenic properties of a novel biomarker in the ICU

机译:为什么高suPAR不能成为ICU中新型生物标志物的超诊断预后和潜在致病特性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The soluble urokinase plasminogen activator receptor (suPAR) has been suggested as a biomarker that reflects immune cell activation. In critically ill patients, several independent investigations have reported elevated suPAR in conditions of systemic inflammatory response syndrome (SIRS), bacteriemia, sepsis, and septic shock, in which high circulating suPAR levels indicated an unfavorable prognosis. In a prospective cohort study in this issue of Critical Care, suPAR levels were detected in bronchoalveolar lavage (BAL) and identified inhalation injury. High systemic levels indicated an adverse prognosis. This study expands our knowledge of the diagnostic power of suPAR, confirms its prognostic value, and raises the demand for future studies investigating the pathogenic involvement of suPAR.
机译:有人建议将可溶性尿激酶纤溶酶原激活剂受体(suPAR)作为反映免疫细胞激活的生物标志物。在重症患者中,一些独立的研究报告说,在全身性炎症反应综合征(SIRS),菌血症,败血症和败血性休克的情况下,suPAR升高,其中高循环suPAR水平表明预后不良。在本期《重症监护》中的一项前瞻性队列研究中,在支气管肺泡灌洗(BAL)中检测到suPAR水平,并确定了吸入性损伤。高全身水平表明不良预后。这项研究扩展了我们对suPAR的诊断能力的认识,证实了其预后价值,并提高了对研究suPAR致病性的研究的需求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号